Ugur Sahin, CEO of German biotech company Piontech, picked up the paper and immediately invited Balachandran’s team to Mainz. During dinner at Helicist, the group discussed the potential of mRNA vaccines to treat pancreatic cancer.
Two years after that session, 20 patients were enrolled in the first clinical trial evaluating mRNA vaccines in patients with pancreatic cancer.
However, the scientific and commercial success of the mRNA vaccine for Covid-19 is still not guaranteed until it stimulated the flow of investment in the sector.
According to the Financial Times, new mRNA therapies are expected to begin entering the market starting in 2025, according to research by the Boston Consulting Group.
Ugur Sahin emphasized that the future of gene therapy to help repair damaged tissues and organs is a potential scientific achievement that messenger RNA can help advance in the coming decades, which may open the way for new genetic therapies such as CRISPR technology.